Bharat Immunological Biological Corporation Ltd vs Jenburkt Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.33 as of 05 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 11.1 on March 2021 to 13.9 on March 2025 . This represents a CAGR of 4.60% over 5 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 182.84 crore on March 2021 to ₹ 446.49 crore on March 2025 . This represents a CAGR of 19.55% over 5 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 48.98 crore as compare to the Dec '25 revenue of ₹ 44.84 crore. This represent the growth of 9.23% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Jenburkt Pharmaceuticals Ltd for the Mar '26 is ₹ 14.65 crore as compare to the Dec '25 ebitda of ₹ 9.24 crore. This represent the growth of 58.55% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 7.42 crore to ₹ 10.85 crore over 8 quarters. This represents a CAGR of 20.92% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Jenburkt Pharmaceuticals Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Jenburkt Pharmaceuticals Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Jenburkt Pharmaceuticals Ltd is 474 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Jenburkt Pharmaceuticals Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Jenburkt Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Jenburkt Pharmaceuticals Ltd?

As of May 5, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.33. On the other hand, Jenburkt Pharmaceuticals Ltd stock price is INR ₹1074.5.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Jenburkt Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Jenburkt Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.